Utilising pre-clinical models to discover novel therapies for tuberculosis

Utilising pre-clinical models to discover novel therapies for tuberculosis

Project details

Intracellular pathogens manipulate host cell survival to facilitate their persistence and dissemination. Our lab investigates these interactions to identify genetic and/or pharmacological strategies of sensitising infected cells to die in vivo. Potential targets are tested in cutting-edge pre-clinical models to determine the effectiveness and feasibility of translation to patients

Students will utilise the Institute’s PC3 high containment facility to work with higher-risk pathogens, namely Mycobacterium tuberculosis. This project employs a pre-clinical model of tuberculosis to make clinically relevant discoveries that are eminently translatable to patient care. We are one of only a few institutes in the world capable of performing this research, and as such, the project will be highly rewarding. Students will become adept in pre-clinical infection models, flow cytometry, histology, molecular biology and tissue culture. 

About our research group

The Pellegrini Lab is interested in chronic infectious diseases, particularly from the perspective of the host. There are many unknowns that surround the failure of the immune system in this setting, which manifests as the death and/or dysfunction of immune cells. 

We work on a range of dangerous yet fascinating pathogens, and have had great success in our highly novel endeavours to utilise different therapeutic agents to enhance the clearance of infected cells. We are also interested in coordinating these approaches with genetic or pharmacological strategies to prevent the premature death of immune cells. We believe that combinatorial approaches such as these will be essential for the cure or long-term remission of chronic infectious diseases, such as tuberculosis, HIV and hepatitis B


Professor Marc Pellegrini

Professor Marc Pellegrini in the lab
Joint Division Head
Cody Allison profile photo
Infectious Diseases and Immune Defence division

Project Type: